top of page

UTHealth Houston
Department of Integrative Biology and Pharmacology 

2025
2025 Snake.jpeg
2025 Snake.jpeg
  • Cancer disease modeling with induced pluripotent stem cells. The Translational Breast Cancer Research Meeting, MD Anderson Cancer Center. October 27, 2025.

2025 MACC talk.jpg
2024
2024 dragon 6.jpeg
2024 dragon 13.jpeg
  • Decoding brain tumors via cellular reprogramming. The Brain Tumor Program Seminar Series. MD Anderson Cancer Center, TX, October 11, 2024

  • Genetics of Osteosarcoma: Unraveling Cancer Initiation. National Tsing Hua University, Taiwan, June 27, 2024

  • Genetics of Osteosarcoma: Unraveling Cancer Initiation. Center for Molecular Medicine (CMM), China Medical University, Taiwan, June 26, 2024

image003.png
2023
48acd04cff908f9ac284a66dfdc1a71e8dfd3bad_edited.jpg
  • Patient-derived iPSCs in Cancer Modeling and Targeted Therapies. The 7th International Conference in Drug Discovery and Lead Optimization, San Francisco, CA, November 1-3 (2023)

  • Paitent-derived iPSCs in Cancer Modeling and Targeted Therapies. 2023 TTBA Symposium, Houston, TX, October 28-29 (2023)

TTBA_DFL.jpg
  • The oncogenic roles of mutant p53 in Li-Fraumeni syndrome associated cancers. Research Center for Cancer Biology. China Medical University, Taiwan., July 26, 2023 (Dr. Ruiying Zhao)

2023 Ruiying Talk.jpg
  • Patient-Derived iPSCs for cancer modeling and targeted Therapies, BIG-TCR program, SBMI, UTHealth Houston, Houston, TX, July 14, 2023

  • Possibility for patient-derived iPSCs in cancer modeling and targeted therapies, McGovern Medical School Research Retreat, Houston, TX, March 7, 2023

2023 Medical School Retreat.tif
  • Induced Pluripotent Stem Cells in Cancer Modeling and Drug Discovery. Department of Pediatrics, MD Anderson Cancer Center, Houston, TX, January 17, 2023

MDACC 2023 talk.jpg
Yang_Hsiang_rescue_his_father_from_a_tiger.jpg
2022
  • Possibilities for patient-derived iPSCs in cancer modeling and targeted therapies. Institue of Biomedical Sciences, Academia Sinica, Taiwan, November 21, 2022

  • Induced Pluripotent Stem Cells in Cancer Modeling and Drug Discovery. National Chung-Hsing University, Taichung, Taiwan, November 18, 2022

  • RB1/E2F Signaling: A Master Regulator of RNA Splicing. National Tsing Hua University, Hsinchu, Taiwan, November 17, 2022

  • RB1/E2F Signaling: A Master Regulator of RNA Splicing. Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, November 11, 2022

  • Possibilities for patient-derived iPSCs in cancer modeling and targeted therapies. 2022 ICCB & APOCB conference, Taipei, Taiwan, November 7, 2022

  • Possibilities for patient-derived iPSCs in cancer modeling and targeted therapies. 2022 International Conference on Advanced Biomedical Sciences ICABS Symposium, Taichung, Taiwan, November 5, 2022

  • Induced Pluripotent Stem Cells in Cancer Modeling and Drug Discovery. Institute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Taiwan, September 26, 2022

IMG_6884.JPG
IMG_6831.JPG
IMG_6783.JPG
IMG_6830.JPG
  • Possibilities for Patient-derived iPSCs in Cancer Modeling and Targeted Therapies. 2022 UTHealth CPRIT CGC Workshop, March 7 2022

CGC workshop.tif
2021
2021%20OX%20stamp_edited.jpg
  • Patient-derived Induced Pluripotent Stem Cells in Cancer Modeling and Targeted Therapies. National Chung-Hsing University, Taiwan, December 16, 2021 (世界百大學校講者線上講座)

2020
rat 2020.png
  • RB1 tumor suppressor and osteosarcomagenesis. Sarcoma Research Group, Houston, TX, May 21 2020

  • Possibilities for Patient-derived iPSCs in Cancer Modeling and Targeted Therapies, St. John's University, New York, NY, October 28, 2020

  • Possibilities for Patient-derived iPSCs in Cancer Modeling and Targeted Therapies. National Chung-Hsing University, Taiwan, December 17, 2020 (世界百大學校講者線上講座)

NCHU talk.tif
2019
2019%2520pig-2_edited_edited.jpg
  • Dissecting and targeting p53-mutant osteosarcoma. Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, March 20, 2019.

  • Dissecting p53-mutant osteosarcoma with LFS iPSCs. Bone Club Meeting, Houston, TX, April 10, 2019.

  • Cancer disease modeling with induced pluripotent stem cells. UTHealth Human Genetics Center Seminar, Houston, TX, April 29, 2019.

  • Dissecting the biology and therapeutic vulnerabilities of RB1-mutant osteosarcoma using RB iPSCs. The 2019 Rolanette and Berdon Lawrence Bone Disease Program of Texas Scientific Retreat, Houston, TX, May 10, 2019

  • How to plan for successful academic career. 2019 The Texas Taiwanese Biotechnology Association (TTBA) symposium, Houston, TX, Jul 13,2019

HGC seminar.tif
MDACC talk-2.tif
2018
2018%20Dog_edited.jpg
  • Reprogramming to fit your scientific career. Cancer biology program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, Jan 18, 2018.

  • Modeling familial cancer syndrome with pluripotent stem cells. UTHealth Center for Precision Health (CPH) Seminar in Precision Medicine, Houston, TX, April 20, 2018.

  • Dissecting cancer etiology in a dish. UTHealth Department of Biochemistry and Molecular Biology Seminar, Houston, TX, May 14, 2018.

  • Dissecting cancer etiology in a dish. A Symposium in Memory and Celebration of Ihor R. Lemischka, Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY, June 14, 2018.

  • Human pluripotent stem cells for modeling cancer. ThermoFisher Scientific Houston Stem Cell Symposium, Houston TX, September 11, 2018.

  • Dissecting osteosarcoma etiology in a dish. Sarcoma Research Group, Houston, TX, October 18, 2018.

ThermoFisher talk.tif
Lemischka talk.tif
CPH talk.tif
2017
2017%20chicken-3_edited.jpg
  • Pluripotent stem cells- opportunities to model familial cancer syndromes. Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan, March 3, 2017.

  • Dissecting cancer etiology in a dish. Dr. Zhongming Zhao’s lab meeting. School of Biomedical Informatics, UTHealth, Houston, April 5, 2017.

  • Pluripotent stem cells- opportunities to model familial cancer syndromes. Department of Molecular Cellular Oncology and Center for Biological Pathways Seminar Series, The University of Texas MD Anderson Cancer Center, Houston, May 3, 2017.

  • Pluripotent stem cells- opportunities to model familial cancer syndromes. Research Center for Developmental Biology and Regenerative Medicine, National Taiwan University, Taipei, Taiwan, June 23, 2017.

  • Pluripotent stem cells- opportunities to model familial cancer syndromes. Institute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Taiwan, June 27, 2017.

  • Dissecting cancer etiology in a dish. Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan, June 28, 2017.

  • Pluripotent stem cells- opportunities to model familial cancer syndromes. Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, July 4, 2017.

  • Dissecting cancer etiology in a dish. Umeå University, Umeå, Sweden, September 15, 2017.

MDACC MCO talk.tif
1060628李東芳博士(林立元教授主持).tif
NTU seminar.tif
2016
2016 Monkey.jpg
  • Modeling Li-Fraumeni syndrome with induced pluripotent stem cells. Dr. Lisa L Wang’s lab meeting. Texas Children’s Hospital, Houston, April 23, 2016

  • Modeling Li-Fraumeni syndrome with induced pluripotent stem cells. Center for Stem Cell & Regenerative Medicine, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, UTHealth, Houston, May 9, 2016.

  • Modeling Li-Fraumeni syndrome with pluripotent stem cells. Society of Chinese Bioscientists in America (SCBA)-Texas Chapter Faculty Club, Houston, September 23, 2016.

  • Modeling cancer with pluripotent stem cells, CMU-MDACC visiting meeting. Department of Molecular Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, December 12, 2016.

The Science & 

Mathematics University

  • UTHealth%20logo_edited
  • Research Gate
  • LinkedIn
  • UTHealth%20logo_edited

© 2023 by Scientist Personal. Proudly created with Wix.com

bottom of page